IP Library Granted Patent US 12,023,383
Granted Patent B2
US 12,023,383 · App. 18/110,654 · Granted Jul 2, 2024

Lipid compositions

Inventors: Muthiah Manoharan (Cambridge, MA); Kallanthottathil G. Rajeev (Cambridge, MA); Muthusamy Jayaraman (Cambridge, MA); David Butler (Medford, MA); Michael E. Jung (Cambridge, MA)
Assignee: ARBUTUS BIOPHARMA CORPORATION
A61K47/22A61K9/1272C07D295/13C12N15/113C12N15/1137C12N2310/14Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,023,383
App. No.
18/110,654
Granted
Jul 2, 2024
Kind
B2
Abstract

Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).

Claims (32)

1. A lipid of formula (I):

or a salt thereof, wherein,

X a and X b , for each occurrence, is independently C 1-6 alkylene;

n is 0, 1, 2, 3, 4, or 5;

A, for each occurrence, is NR 2 or a cyclic moiety optionally substituted with 1-3 R;

B is NR or a cyclic moiety optionally substituted with 1-2 R;

each R is independently H, alkyl,

provided that at least one R is

R 1 , for each occurrence, is independently H, R 3 ,

R 2 , for each occurrence, is independently, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl;

R 3 , for each occurrence, is independently, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl;

Y, for each occurrence, is O;

R 4 , for each occurrence is independently H alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl.

2. The lipid of claim 1 , wherein n is 1 or 2.

3. The lipid of claim 1 , wherein A for each occurrence is NR 2 .

4. The lipid of claim 1 , wherein B is a cyclic moiety.

5. The lipid of claim 1 , wherein B is a nitrogen containing cyclic moiety.

6. The lipid of claim 1 , wherein B is piperidinyl or piperizinyl moiety.

7. The lipid of claim 1 , wherein each R is independently

8. The lipid of claim 1 , wherein R 1 , for each occurrence, is H.

9. The lipid of claim 1 , wherein R 2 , for each occurrence, is independently alkyl.

10. The lipid of claim 1 , wherein R 2 , for each occurrence, is independently, alkenyl.

11. The lipid of claim 1 , wherein n is 1 or 2; A is NR 2 ; B is NR or a cyclic moiety; R 1 is H; R 2 is independently alkyl or alkenyl; Y is O; and R is

12. The lipid of claim 1 , wherein n is 1; A is NR 2 ; B is a cyclic moiety; R 1 is H; R 2 is independently alkyl or alkenyl; Y is O; and R is

13. A composition, the composition comprising a sterol, a neutral lipid, a PEG or a PEG-modified lipid, and a lipid as described in claim 1 .

14. The composition of claim 13 , wherein the sterol is cholesterol.

15. The composition of claim 13 , wherein the PEG or PEG-modified lipid is a PEG-modified lipid.

16. The composition of claim 13 , wherein the composition is a liposome.

17. The composition of claim 13 , further comprising therapeutic agent.

18. The composition of claim 17 , wherein the therapeutic agent is a nucleic acid agent.

19. The composition of claim 17 , wherein the therapeutic agent is siRNA.

20. The composition of claim 17 , wherein the therapeutic agent is mRNA.

Assignments (4)
MERGER Recorded Jan 20, 2024
From: PROTIVA BIOTHERAPEUTICS, INC.
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 066357/0241 →
CHANGE OF NAME Recorded Dec 7, 2023
From: TEKMIRA PHARMACEUTICALS CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 065802/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2023
From: ALNYLAM PHARMACEUTICALS, INC.
To: TEKMIRA PHARMACEUTICALS CORPORATION
Reel/Frame 065672/0746 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2023
From: MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; JAYARAMAN, MUTHUSAMY; BUTLER, DAVID; JUNG, MICHAEL E.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 065611/0692 →